Physician profile
Craig A Kuhns
NPI 1922038108
$2,395,059.08
in general payments reported to CMS, 2019-2025
31 companies · $624K in 2025
The $624K reported for 2025 was more than what 99% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $145K · 2021: $241K · 2022: $337K · 2023: $437K · 2024: $534K · 2025: $624K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.5M · Consulting Fee: $55K · Travel and Lodging: $14K · Food and Beverage: $7,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,520,049.83 |
| Consulting Fee | $54,571.50 |
| Travel and Lodging | $13,770.50 |
| Food and Beverage | $7,219.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $2,174,129.05 | 2019-2025 | Invictus Open, Other - Miscellaneous, Invictus Vise |
| Nuvasive, INC. | $75,310.17 | 2019-2023 | Reline |
| Globus Medical, INC. | $48,067.08 | 2024-2025 | Reline, Creo |
| Spineology INC. | $36,337.39 | 2019-2021 | |
| Medtronic, INC. | $35,912.58 | 2024-2025 | Stealthstation S8 Platform, Anteralign Spinal System With Titan Nanolock Surface Technology, Unid_pass |
| Spineart USA INC | $6,276.29 | 2020-2024 | |
| Surgalign Spine Technologies, INC. | $5,877.53 | 2019 | |
| Si-Bone, INC. | $3,719.75 | 2019-2025 | |
| Cerapedics INC. | $3,018.74 | 2021-2024 | I-Factor Peptide Enhanced Bone Graft |
| Stryker Corporation | $1,741.30 | 2019-2022 | |
| Arthrex, INC. | $1,547.68 | 2022 | |
| Medinc of Texas | $724.51 | 2022-2023 | |
| Acuity Surgical Devices, LLC | $579.01 | 2025 | |
| Providence Medical Technology, INC. | $342.28 | 2020-2022 | |
| Abbott Laboratories | $287.16 | 2019-2024 | Proclaim |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $255.43 | 2019-2023 | Teligen |
| Abyrx, INC | $213.26 | 2019 | |
| Zimmer Biomet Holdings, INC. | $158.97 | 2019 | |
| Kuros Biosciences USA, INC | $112.28 | 2022 | |
| Xtant Medical INC | $107.13 | 2024 | |
| Boston Scientific Corporation | $87.21 | 2025 | General - Pain Management |
| Medtronic USA, INC. | $62.36 | 2019-2020 | |
| Carlsmed, INC. | $62.00 | 2023 | Aprevo |
| Seaspine Orthopedics Corporation | $29.53 | 2022 | |
| Centinel Spine, LLC | $26.41 | 2019 | |
| Core Surgical Group | $25.53 | 2025 | |
| Olympus America INC. | $19.80 | 2023 | |
| Misonix INC | $15.70 | 2019 | |
| Relievant Medsystems, INC. | $12.95 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$29,924.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$1,667,891.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Kuhns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.